The mechanism of its actions is thought to be related to the selective inhibition of viral RNA-dependent RNA polymerase.<unk>  is a prodrug that is metabolized to its active form,<unk> -ribofuranosyl-5'-triphosphate<unk> -RTP), available in both oral and intravenous formulations. In 2014,<unk>  was approved in Japan for stockpiling against influenza pandemics. However,<unk>  has not been shown to be effective in primary human airway cells, casting doubt on its efficacy in influenza treatment.<unk>  ribofuranosyl triphosphate, the active form inside the body<unk> -RTP is a nucleoside analogue. It mimics both guanosine and adenosine for the viral RdRP. Incorporating two such bases in a row stops primer extension, although it's unclear how as of 2013.
Favipiravir
Balapiravir
Odalasvir
Ledipasvir
Telaprevir
Molnupiravir
Taribavirin
Saquinavir